enGene Therapeuti…
CACADenGene Therapeutics Inc. (US:ENGN) — Biotechnology: Biological Products (No Diagnostic Substances). Брой борси, на които се търгуват акциите на компанията: 1. На тази страница — цена и график, дивиденти, най-големи акционери и история на броя на акциите.
За Компанията
- Уебсайт
- engene.com
- Сектор
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Централа
- SAINT-LAURENT, Canada
- Изпълнителен Директор
- Ronald H. W. Cooper
- Служители
- 81
- Акции в Обращение
- 67.02 млн към 2026-09-02
- Свободно Търгуеми Акции
- 32.75 млн
- Пазарна Капитализация
- 132.02 млн USD
- Инсайдери
- 0.11%
- Институционални Инвеститори
- 84.11%
- Отрасъл (SIC)
- Biological Products, (No Diagnostic Substances)
- P/E
- загуба
- FCF
- −104 млн USD
- Дълг
- 25.2 млн USDнетни парични средства
- Печалби и FCF — за 12-те месеца до 31.07.2026 (последният доклад на компанията).
Описание
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Борси и Тикери
| Борса | Тикер | Валута | Цена | Вид |
|---|---|---|---|---|
| US USA Stocks | ENGN | USD | 1.73 -2.81% | обикновени акции |
Най-Големи Притежатели
| Притежател | Дял | Акции | Дата на Доклада |
|---|---|---|---|
| FCPM III Services B.V. | 14.37% | 9.63 млн | 2026-06-30 |
| BML Capital Management,… | 9.95% | 6.67 млн | 2026-06-30 |
| Siren, L.L.C. | 9.34% | 6.26 млн | 2026-06-30 |
| Perceptive Advisors Llc | 7.2% | 4.82 млн | 2026-06-30 |
| Ameriprise Financial, In… | 3.99% | 2.68 млн | 2026-06-30 |
| Nextech Invest, Ltd. | 3.47% | 2.32 млн | 2026-06-30 |
| Adar1 Capital Management… | 3.14% | 2.1 млн | 2026-06-30 |
| Vestal Point Capital, LP | 2.49% | 1.67 млн | 2026-06-30 |
| Acorn Capital Advisors,… | 1.9% | 1.27 млн | 2026-06-30 |
| Peapod Lane Capital LLC | 1.64% | 1.1 млн | 2026-06-30 |
| Franklin Strategic Serie… | 0.73% | 486 579 | 2026-04-30 |
| Fidelity Concord Street… | 0.05% | 34 982 | 2026-07-31 |
| ETFis Series Trust I-Vir… | 0.05% | 32 625 | 2026-04-30 |
| TIFF INVESTMENT PROGRAM-… | 0.02% | 10 639 | 2026-06-30 |
| JNL Series Trust-JNL/DFA… | 0.01% | 9 974 | 2026-06-30 |
| Exchange Place Advisors… | 0.01% | 7 649 | 2026-06-30 |
| GROSSMAN WILLIAM (Office… | ≈0.01% | 5 102 | 2026-09-22 |
| Advanced Series Trust-AS… | 0% | 1 376 | 2026-06-30 |
| FORBION GROWTH OPPORTUNI… | — | — | 2024-10-30 |
